Cancer cells expressing CA IX generally represent the most aggressive fraction of tumor tissue (with exception of ccRCC), and thus, CA IX–based stratification with tissue and serum biomarkers or imaging, followed by targeting of CA IX-expressing tumors, are anticancer strategies that are worth following, as supported by a number of preclinical models and clinical experiences. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.